A retrospective study of 135 pediatric BBS patients reveals high prevalence of obesity (77.6%) and short stature (21.1%), with low rates of hypogonadism, hypothyroidism, and glucose metabolism disorders compared to adult populations.
A nationwide study reveals that pre-pregnancy BMI and diabetes status significantly influence gestational age-specific stillbirth risks, with obese diabetic women facing the highest absolute risks, necessitating tailored delivery timing strategies.
A study of 1,454 older adults with metabolic syndrome reveals that long-term exposure to air pollutants like black carbon, PM2.5, and NO2 is associated with increased fat mass and decreased lean mass, persisting over three years, particularly in those under 65.
A multicenter retrospective cohort study reveals that metabolic bariatric surgery in 162 adults with type 1 diabetes and obesity achieved 29.7% weight loss at one year, reduced insulin requirements by 57%, and significantly improved glycemic and lipid profiles, suggesting MBS as a viable option for this high-risk population.
This emulation study applies SELECT trial data to over 600,000 individuals, suggesting that GLP-1RAs could significantly reduce 10-year cardiovascular risk in high-risk obese populations without existing disease, offering a potential 22% relative risk reduction.
A massive study of nearly 290,000 participants reveals that severe obesity (BMI ≥40) triples the risk of heart failure and nearly triples the risk of atrial fibrillation, with significant sex-based differences in stroke and mortality risk.
This review synthesizes recent evidence on how Vitamin D mitigates high-fat diet-induced testicular and sperm dysfunction, focusing on hormonal recovery, blood-testis barrier stabilization, and mitochondrial protection.
This review synthesizes findings from a 21-
**Compiling final edits**
Now that I've structured the article, I'm focusing on the final touches, particularly the content for the "Highlights," "Expert Commentary," and the "Conclusion" sections. I'm leveraging the provided literature, including the Dardari et al. study and related papers on GLP-1 agonists and dietary patterns, to build a cohesive narrative. The JSON schema is in its final phase of completion. I have successfully populated the `relative_articles` field.
cohort study on 289,875 individuals, demonstrating that severe obesity (BMI ≥35 kg/m²) dramatically elevates risks for heart failure and atrial fibrillation, while revealing significant sex-based differences in stroke and mortality risk.
A large-scale multicohort study reveals that adult obesity significantly increases the risk of hospitalization and death across nearly 1,000 infectious diseases, accounting for approximately one in ten infection-related deaths globally.
The World Health Organization (WHO) has released its landmark 2026 guidelines on GLP-1 therapies for obesity, reclassifying the condition as a chronic, relapsing disease requiring long-term pharmacological and behavioral management while emphasizing global health equity.
A simulation study reveals that while semaglutide significantly reduces cardiovascular events in adults with obesity, its current cost exceeds traditional cost-effectiveness thresholds, requiring an 18% price reduction for broader economic viability.
This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream strategy for rhythm control.
This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a critical adjunctive therapy in metabolic-arrhythmic management.
The Sweet Tooth Trial reveals that reducing dietary sweet exposure for six months does not decrease sweet taste liking, calorie intake, or weight, questioning the efficacy of current public health strategies centered solely on reducing sweet-tasting food exposure.
The REDEFINE 1 trial demonstrates that CagriSema, a semaglutide/cagrilintide combination, significantly reduces blood pressure in adults with overweight or obesity, even among those with resistant hypertension, while facilitating the reduction of concomitant antihypertensive medications.
This article compares the Ketogenic and Mediterranean diets' impact on cardiovascular markers and mental health, highlighting results from two recent pilot studies on blood pressure and the gut-brain axis.
This review synthesizes recent breakthroughs in obesity, type 2 diabetes, and lipidology, focusing on oral orforglipron, zodasiran for HoFH, and adolescent metabolic risk factors.
The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight by 16% in Asian adults with obesity (BMI ≥25 kg/m2), providing robust evidence for population-specific clinical guidelines and reimbursement policies in South Korea and Thailand.
A post hoc analysis of the LEAN-TIME trial reveals that integrating gut microbiome and metabolomic data with clinical phenotypes significantly improves the prediction of weight loss and regain, offering a framework for precision weight management and personalized obesity care.
A Phase 2 trial demonstrates that tirzepatide significantly reduces body weight, HbA1c, and total daily insulin requirements in adults with type 1 diabetes and obesity, offering a promising therapeutic strategy for managing metabolic health in this population.